About N(6)-adenine-specific methyltransferase METTL4
N(6)-adenine-specific methyltransferase METTL4 (METTL4) is a protein
from Homo sapiens identified by UniProt accession
Q8N3J2, 472 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | N(6)-adenine-specific methyltransferase METTL4 |
| UniProt accession | Q8N3J2 |
| Gene | METTL4 |
| Organism | Homo sapiens |
| Length | 472 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (67)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.32
- diffuse plaque measurement · score 0.22
- gut microbiome measurement · score 0.22
- nervous system disease · score 0.22
- medical procedure · score 0.22
- PHF-tau measurement · score 0.13
- neoplasm · score 0.08
- melanoma · score 0.05
- Blackfan-Diamond anemia · score 0.05
- hemoglobin D disease · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N3J2-F1 | alphafold | PREDICTED | 77.21 | — |
Amino-acid sequence (472 residues)
MSVVHQLSAG WLLDHLSFIN KINYQLHQHH EPCCRKKEFT TSVHFESLQM DSVSSSGVCA AFIASDSSTK PENDDGGNYE MFTRKFVFRP ELFDVTKPYI TPAVHKECQQ SNEKEDLMNG VKKEISISII GKKRKRCVVF NQGELDAMEY HTKIRELILD GSLQLIQEGL KSGFLYPLFE KQDKGSKPIT LPLDACSLSE LCEMAKHLPS LNEMEHQTLQ LVEEDTSVTE QDLFLRVVEN NSSFTKVITL MGQKYLLPPK SSFLLSDISC MQPLLNYRKT FDVIVIDPPW QNKSVKRSNR YSYLSPLQIQ QIPIPKLAAP NCLLVTWVTN RQKHLRFIKE ELYPSWSVEV VAEWHWVKIT NSGEFVFPLD SPHKKPYEGL ILGRVQEKTA LPLRNADVNV LPIPDHKLIV SVPCTLHSHK PPLAEVLKDY IKPDGEYLEL FARNLQPGWT SWGNEVLKFQ HVDYFIAVES GS
Explore N(6)-adenine-specific methyltransferase METTL4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets